BIOLITEC AG OBTAINS LICENSE FROM VALENTIS

Biolitec AG today announced that it has obtained an exclusive worldwide license for development and commercialization of innovative drug formulations using the Pegylated liposome technology of Valentis of Burlingame, CA, through its associate, Biolitec Pharma Marketing. Under the terms of the licensing agreement, Valentis will receive an upfront payment and is entitled to milestone payments and to royalties on commercial product sales.

Yahoo News (http://biz.yahoo.com/prnews/050622/nyw038.html?.v=12)